First program in preclinical phase for Retinitis Pigmentosa (RP), and four programs in lead nomination for DMD, DM1, ALS and AD.
The lead compounds normalise calcium levels and protect from oxidative stress damage.
Solid IP Position: Patents covering the main markets.
First rate management team with many years of experience in the field of Neurodegenerative and Rare diseases, from basic research to clinical practice. Supported by a high-level advisory board.
For detailed information about the progress of the company or investing options, leave us a message and we will organize a video meeting with your team.